Abstract
No field more eagerly awaits a molecular clarification for G-protein coupled receptor (GPCR) dimerization than the opioid receptor field. Extensive evidence of pharmacological and functional interactions between opioid receptor types has primed this field for such a resolution. In retrospect, much of the data collected on synergy between different opioid receptor types may represent the functional correlate for the newly found opioid receptor dimerization. While previous reports of functional synergy have been, for the most part, consistent in demonstrating cross-regulation between two receptor types, the lack of highly receptor-selective ligands allowed skeptics to remain doubtful over the interpretations of these results. Today, two important developments in the opioid receptor field help reinvigorate the hypothesis of functional, cross-modulating opioid receptor complexes: (1) The existence of highly selective ligands which eliminate any possibility of cross-reactivity between receptor types, and (2) the discovery that opioid receptors and a number of other GPCRs exist as dimers in biochemical, functional and pharmacological assays. It is with these new tools that we seek to understand the mechanisms and implications of dimerization. Initial results of these studies have demonstrated that the dimerization of opioid receptors may help consolidate several pharmacological findings that have remained unanswered. In this review we present biochemical, pharmacological and functional evidence for opioid receptor complexes and add evidence from our recent studies on opioid receptor dimerization. We believe a thorough understanding of receptor dimerization is crucial in clarifying the mechanism of action of opioids and other drugs and may serve a more practical purpose in aiding the development of novel therapeutic drugs. [Neruopsychopharmacology 23:S5–S18, 2000]
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Agarwal D, Glasel J . (1993): Co-localization of mu and delta opioid receptors on SK-N-SH cells detected by fluorescence microscopy using labeled anti-idiotypic antibodies. Life Sci 52: 193–198
Aley K, Levine J . (1997): Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. J Neurosci 17: 735–744
Audiger Y, Attali B, Mazsarguil H, Cros J . (1982): Characterization of [3H]-etorphine binding in guinea pig striatum after blockade of mu and delta sites. Life Sci 31: 1287–1290
Barrett R, Vaught J . (1982): The effects of receptor selective opioid peptides on morphine-induced analgesia. Eur J Pharmacol 80: 427–430
Baumhaker Y, Wollman Y, Goldstein M, Sarne Y . (1993): Evidence for mu-, delta-, and kappa-opioid receptors in a human neuroblastoma cell line. Life Sci 52: 205–210
Biscoe T, Duggan A, Lodge D . (1972): Effect of etorphine, morphine and diprenorphine on neurones of the cerebral cortex and spinal cord of the rat. Br J Pharmacol 46: 201–212
Blane G, Boura A, Fitzgerald A, Lister R . (1967): Actions of etorphine hydrochloride, (M99): a potent morphine-like agent. Br J Pharmacol 30: 11–22
Bowen W, Gentleman S, Herkenham M, Pert C . (1981): Interconverting mu and delta forms of the opiate receptor in rat striatal patches. Proc Natl Acad Sci USA 78: 4818–4822
Bradbury A, Smyth D, Snell C, Birdsall N, Hulme E . (1976): C-fragment of lipoprotein has a high affinity for brain opiate receptors. Nature (London)260: 793–795
Brown S, Stimmel B, Taub R, Kochwa S, Rosenfield R . (1974): Immulogic dysfunction in heroin addicts. Arch Intern Med 134: 1001–1014
Chang K, Cuatrecasas P . (1979): Multiple opiate receptors. Enkephalins and morphine bind to receptors of different specificity. J Biol Chem 254: 2610–2618
Chen Y, Mestek A, Liu J, Hurley J, Yu L . (1993): Molecular cloning and fuctional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44: 8–12
Cheng P, Liu-Chen L, Pickel V . (1997): Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res 778: 367–380
Chu P, Murray S, Lissin D, von Zastrow M . (1997): Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist. J Biol Chem 272: 27124–27130
Cotton R, Giles M, Miller L, Shaw J, Timms D . (1984): ICI 174864: a highly selective antagonist for the opioid delta-receptor. Eur J Pharmacol 97: 331–332
Cox B, Goldstein A, Li C . (1976): Opioid activity of a peptide, beta-endorphin (61-91), derived from beta-lipotropin. Proc Natl Acad Sci USA 73: 1821–1823
Cvejic S, Devi L . (1997): Dimerization of the δ opioid receptor: implication for a role in receptor internalization. J Biol Chem 272: 26959–26964
D'Amato R, Holaday J . (1984): Multiple opioid receptors in endotoxic shock: evidence for delta involvement and mu-delta interactions in vivo. Proc Natl Acad Sci USA 81: 2898–2901
Dawson-Basoa M, Gintzler A . (1998): Gestational and ovarian sex steroid antinociception: synergy between spinal kappa and delta opioid systems. Brain Res 794: 61–67
Demoliou-Mason C, Barnard E . (1986a): Characterization of opioid receptor subtypes in solution. J Neurochem 46: 1129–1136
Demoliou-Mason C, Barnard E . (1986b): Distinct subtypes of the opioid receptor with allosteric interactions in brain membranes. J Neurochem 46: 1118–1128
Devi LA, Jordan BA, Trapaidze N, Nivarthi R, Nagy V, Gupta A, Bansinath M, Gomes I : G-protein couple receptor dimerization: a review. J Mol Med (in press).
Dixon W, Viveros O, Unsworth C, Diliberto EJ, Way E, Lewis J, Chandra A, Holaday J, Long J, Tortella F . (1985): Multiple opiate receptors: functional implications. Fed Proc 44: 2851–2862
Egan T, North R . (1981): Both mu and delta opiate receptors exist on the same neuron. Science 214: 923–924
Erspamer V, Melchiorri P, Falconieri-Erspamer G, Negri L, Corsi R, Severini C, Barra D, Simmaco M, Kreil G . (1989): Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. Proc Natl Acad Sci USA 86: 5188–5192
Evans C, Keith Jr, D, Morrison H, Magendzo K, Edwards R . (1992): Cloning of a delta opioid receptor by functional expression. Science 258: 1952–1955
Fields H, Emson P, Leigh B, Gilbert R, Iversen L . (1980): Multiple opiate receptor sites on primary afferent fibres. Nature 284: 351–353
Gacel G, Fournie-Zaluski M, Roques B . (1980): D-Tyr–Ser-Gly–Phe–Leu–Thr, a highly preferential ligand for delta-opiate receptors. FEBS Lett 118: 245–247
Garzon J, Jen M, Sanchez-Blazquez P, Lee N . (1982): Dynorphin(1-13), a long-lasting inhibitor of opiate receptor binding in vitro. Life Sci 31: 1789–1792
Garzon J, Juarros J, Castro M, Sanchez-Blazquez P . (1995): Antibodies to the cloned mu-opioid receptor detect various molecular weight forms in areas of mouse brain. Mol Pharmacol 47: 738–744
Genazzani A, Petraglia F . (1989): Opioid control of leutinizing hormone secretion in humans. J Steroid Biochem 33: 751–755
Gintzler A, Pasternak G . (1983): Multiple mu receptors: evidence for mu2 sites in the guinea pig ileum. Neurosci Lett 39: 51–56
Goldstein A, Fischli W, Lowney L, Hunkapiller M, Hood L . (1981): Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci USA 78: 7219–7223
Handa B, Land A, Lord J, Morgan B, Rance M, Smith C . (1981): Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur J Pharmacol 70: 531–540
Hazum E, Chang K, Cuatrecasas P . (1979): Role of disulphide and sulphydryl groups in clustering of enkephalin receptors in neuroblastoma cells. Nature 282: 626–628
Hazum E, Chang K, Leighton H, Lever O Jr, Cuatrecasas P . (1982): Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking. Biochem Biophys Res Commun 104: 347–353
Herz A . (1993): Opioids. Berlin, Springer-Verlag, Vol. 1
Heyman J, Vaught J, Mosberg H, Haaseth R, Porreca F . (1989): Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2,D-Pen5]enkephalin. Eur J Pharmacol 165: 1–10
Hughes J, Smith T, Kosterlitz H, Forthergill L, Morgan B, Morris H . (1975): Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (London)258: 577–579
Jiang Q, Bowen W, Mosberg H, Rothman R, Porreca F . (1990a): Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site. J Pharmacol Exp Ther 255: 636–641
Jiang Q, Mosberg H, Porreca F . (1990b): Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Pharmacol Exp Ther 254: 683–689
Jiang Q, Mosberg H, Porreca F . (1990c): Selective modulation of morphine antinociception, but not development of tolerance, by delta receptor agonists. Eur J Pharmacol 186: 137–141
Jiang Q, Takemori A, Sultana M, Portoghese P, Bowen W, Mosberg H, Porreca F . (1991): Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]-enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther 257: 1069–1075
Jordan B, Cvejic S, Devi L . (2000): Kappa opioid receptor endocytosis by dynorphin peptides. DNA Cell Biol 19: 19–27
Jordan B, Devi L . (1999): G-protein coupled receptor heterodimerization modulates receptor function. Nature 399: 697–700
Kakidani H, Furutani Y, Takahashi H, Noda M, Morimoto Y, Hirose T, Asai M, Inayama S, Nakanishi S, Numa S . (1982): Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/dynorphin precursor. Nature (London)298: 245–249
Kamei J, Tanihara H, Kasuya Y . (1991): Modulation of mu-mediated antitussive activity in rats by a delta agonist. Eur J Pharmacol 203: 153–156
Kazmi S, Mishra R . (1987): Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 32: 109–118
Kieffer B, Befort K, Gaveriaux-Ruff C, Hirth C . (1992): The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 89: 12048–12052
Kosterlitz H, Lord J, Paterson S, Waterfield A . (1980): Effects of changes in the structure of enkephalins and of narcotic analgesic drugs on their interactions with mu- and delta-receptors. Br J Pharmacol 68: 333–342
Lahti R, Mickelson M, McCall J, Von Voigtlander P . (1985): [3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol 109: 281–284
Lee N, Leybin L, Chang J, Loh H . (1980): Opiate and peptide interaction: effect of enkephalins on morphine analgesia. Eur J Pharmacol 68: 181–185
Li J-G, Luo L-Y, Krupnick J, Benovic J, Liu-Chen L . (1999): U50-488H-induced internalization of the human K opioid receptor involves B-arrestin and dynamin-dependent mechanism. J Biol Chem 274: 12087–12094
Lord J, Waterfield A, Hughes J, Kosterlitz H . (1977): Endogenous opioid peptides: multiple agonists and receptors. Nature 267: 495–499
MacDonald RL, Nelson PG . (1978): Specific-opiate-induced depression of transmitter release from dorsal root ganglion cells in culture. Science 199: 1449–1451
Maggi R, Pimpinelli F, Martini L, Piva F . (1995): Inhibition of leutinizing hormone-releasing hormone secretion by delta-opioid agonists in GT1-1 neuronal cells. Endocrinology 136: 5177–5181
Martin W, Eades C, Thompson J, Huppler R, Gilbert P . (1976): The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517–532
Matthes H, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques B, Kieffer B . (1996): Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383: 819–823
Mattia A, Vanderah T, Mosberg H, Porreca F . (1991): Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5] enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther 258: 583–587
Miaskowski C, Taiwo Y, Levine J . (1990): Kappa- and delta-opioid agonists synergize to produce potent analgesia. Brain Res 509: 165–168
Miaskowski C, Taiwo Y, Levine J . (1993): Antinociception produced by receptor selective opioids. Modulation of supraspinal antinociceptive effects by spinal opioids. Brain Res 608: 87–94
Mosberg H, Hurst R, Hruby V, Gee K, Yamamura H, Galligan J, Burks T . (1983): Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci USA 80: 5871–5874
Mudge A, Leeman SE, Fischbach GD . (1979): Enkephalin inhibits the release of substance P from sensory neurons in culture and decreases action potential duration. Proc Natl Acad Sci USA 76: 526–530
Nakanishi S, Inoue A, Kita T, Nakamura M, Chang A, Cohen S, Numa S . (1979): Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature (London)278: 423–427
Nock B, Rajpara A, O'Connor L, Cicero T . (1988): [3H]U-69593 labels a subtype of kappa opiate receptor with characteristics different from that labeled by [3H]ethylketocyclazocine. Life Sci 42: 2403–2412
Noda M, Furutani Y, Takahashi H, Toyosato M, Hirose T, Inayama S, Nakanishi S, Numa S . (1982): Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature (London)295: 202–206
Palazzi E, Ceppi E, Guglielmetti F, Catozzi L, Amoroso D, Groppetti A . (1996): Biochemical evidence of functional interaction between mu- and delta-opioid receptors in SK-N-BE neuroblastoma cell line. J Neurochem 67: 138–144
Pasternak G, Simantov R, Snyder S . (1976): Characterization of an endogenous morphine-like factor (enkephalin) in mammalian brain. Mol Pharmacol 12: 504–513
Paterson S, Robson L, Kosterlitz H . (1983): Classification of opioid receptors. Br Med Bull 39: 31–36
Pert C, Snyder S . (1973): Opiate receptor: demonstration in nervous tissue. Science 179: 1011–1014
Polastron J, Mur M, Mazarguil H, Puget A, Meunier J, Jauzac P . (1994): Sk-n-be: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. J Neurochem 62: 898–906
Porreca F, Takemori A, Sultana M, Portoghese P, Bowen W, Mosberg H . (1992): Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther 263: 147–152
Portoghese P, Larson D, Sayre L, Fries D, Takemori A . (1980): A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities. J Med Chem 23: 233–234
Portoghese P, Sultana M, Nagase H, Takemori A . (1992a): A highly selective delta 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol 218: 195–196
Portoghese P, Sultana M, Nelson W, Klein P, Takemori A . (1992b): Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes. J Med Chem 35: 4086–4091
Portoghese P, Sultana M, Takemori A . (1988): Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146: 185–186
Quirion R, Bowen W, Herkenham M, Pert C . (1982): Visualization and solubilization of rat brain opiate receptors with a “kappa” ligand selectivity pattern. Cell Mol Neurobiol 1982: 333–346
Rice K, Jacobson A, Burke TJ, Bajwa B, Streaty R, Klee W . (1983): Irreversible ligands with high selectivity toward delta and mu opiate receptors. Science 220: 314–316
Rocheville M, Lange D, Kumar U, Sasi R, Patel R, Patel Y . (2000): Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275: 7862–7869
Romer D, Buscher H, Hill R, Maurer R, Petcher T, Welle H, Bakel H, Akkerman A . (1980): Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci 27: 971–978
Rothman R, Danks J, Pert C, Jacobson A, Burke TJ, Rice K . (1984): Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro. Neuropeptides 4: 261–268
Rothman R, Westfall T . (1981): Allosteric modulation by leucine-enkephalin of [3H]naloxone binding in rat brain. Eur J Pharmacol 72: 365–368
Rothman R, Westfall T . (1982): Allosteric coupling between morphine and enkephalin receptors in vitro. Mol Pharmacol 21: 548–557
Roy S, Loh H . (1996): Effects of opioids on the immune system. Neurochem Res 21: 1375–1386
Sanchez-Blazquez P, Garcia-Espana A, Garzon J . (1997): Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J Pharmacol Exp Ther 280: 1423–1431
Schafer M, Martin R . (1994): Opioid peptides in the pituitary: a hormone, a panacrine modulator and a peptide in search of function. Biol Chem Hoppe Seyler 375: 737–740
Schiller P, Fundytus M, Merovitz L, Weltrowska G, Nguyen T, Lemieux C, Chung N, Coderre T . (1999): The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 42: 3520–3526
Schoffelmeer A, Yao Y, Gioannini T, Hiller J, Ofri D, Roques B, Simon E . (1990): Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex. J Pharmacol Exp Ther 253: 419–426
Sheldon R, Nunan L, Porreca F . (1989): Differential modulation by [D-Pen2, D-Pen5]enkephalin and dynorphin A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo. J Pharmacol Exp Ther 249: 462–469
Shimohigashi Y, Takano Y, Kamiya H, Costa T, Herz A, Stammer C . (1988): A highly selective ligand for brain delta opiate receptors, a cyclopropyl(E)Phe(4)-enkephalin analog, suppresses mu receptor-mediated thermal analgesia by morphine. FEBS Lett 233: 289–293
Simon J, Hiller J, Edelman I . (1973): Stereospecific binding of the potent narcotic analgesic 3H etorphine to rat brain homogenate. Proc Natl Acad Sci USA 70: 1947–1949
Sofuoglu M, Portoghese P, Takemori A . (1991): Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther 257: 676–680
Terenius L . (1973): Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Phamacol Toxicol 32: 317–319
Traynor J . (1989): Subtypes of k-opioid receptor: fact or fiction? Trends Pharmacol Sci 10: 52–53
Traynor J, Elliot J . (1993): δ-opioid receptor subtypes and cross talk with μ-receptors. Trends Pharmacol Sci 14: 84–85
Vaught J, Takemori A . (1979): Differential effects of leucine enkephalin and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. J Pharmacol Exp Ther 208: 86–94
Xu H, Partilla J, de Costa B, Rice K, Rothman R . (1993): Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: further evidence for delta receptor heterogeneity. Peptides 14: 893–907
Yaksh TL . (1993): New horizons in our understanding of the spinal physiology and pharmacology of pain processing. Semin Oncol 20: 6–18
Yasuda K, Raynor K, Kong H, Breder C, Takeda J, Reisine T, Bell G . (1993): Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 90: 6736–6740
Yu V, Richards M, Sadee W . (1986): A human neuroblastoma cell line expresses mu and delta opioid receptor sites. J Biol Chem 261: 1065–1070
Zadina J, Hackler L, Ge L, Kastin A . (1997): A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386: 499–502
Zhu Y, King M, Schuller A, Nitsche J, Reidl M, Elde R, Unterwald E, Pasternak G, Pintar J . (1999): Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 24: 243–252
Zieglgansberger W, French E, Mercuri N, Pelayo F, Williams J . (1982): Multiple opiate receptors on neurons of the mammalian central nervous system. Life Sci 31: 2343–2346
Zimprich A, Simon T, Hollt V . (1995): Cloning and expression of an isoform of the rat mu opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett 359: 142–146
Zukin R, Eghbali M, Oliver D, Unterwald E, Tempel A . (1988): Characterization and visualization of rat and guinea pig brain κ opioid receptors: evidence for κ1 and κ2 opioid receptors. Proc Natl Acad Sci USA 85: 4061–4065
Acknowledgements
This work was supported in part by NIH grants DA 08863 and DA 00458 (to LAD) and National Research Service Award Grant DA05885 (to BAJ).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jordan, B., Cvejic, S. & Devi, L. Opioids and Their Complicated Receptor Complexes. Neuropsychopharmacol 23 (Suppl 1), S5–S18 (2000). https://doi.org/10.1016/S0893-133X(00)00143-3
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00143-3
Keywords
This article is cited by
-
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
Journal of Gastroenterology (2014)
-
A molecular dynamics study on opioid activities of biphalin molecule
Journal of Molecular Modeling (2011)
-
The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk
Molecular Psychiatry (2008)
